ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a U.S.-based biopharmaceutical company built around neffy, a needle-free intranasal epinephrine product for the emergency treatment of Type I allergic reactions, including anaphylaxis. The company describes neffy as the first and only FDA- and European Commission-approved needle-free epinephrine product, with additional approvals in the U.K., Japan, Australia, and China. Its business is centered on commercializing neffy in the United States while expanding through licensing and collaboration partners in international markets. ARS also has a development program in chronic urticaria, but near-term value creation is primarily tied to neffy adoption, reimbursement, and geographic expansion.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved needle-free intranasal epinephrine products sold for emergency treatment of anaphylaxis.
Milestone, royalty, and service revenue from licensing and commercialization partners.
Revenue from supplying product or related materials to partners under collaboration arrangements.
Products
Reported · share of revenue- Products85.7 %
- Revenue Under Collaboration Agreements11.5 %
- Revenue Under Supply Agreements2.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
ARS sells primarily into the U.S. prescription allergy market, where the key buyers are healthcare providers who prescribe epinephrine for patients at risk of anaphylaxis. The company specifically targets high-volume prescribers such as allergists and pediatricians, because these physicians account for a large share of epinephrine prescriptions and are most likely to adopt a non-injectable option. In the U.S., product distribution runs through pharmaceutical wholesale distributors, which are the channel that ultimately supplies pharmacies and healthcare providers. Outside the U.S., ARS relies on licensing partners such as Alfresa, Pediatrix, Seqirus, and ALK to commercialize in their respective territories, so partner execution is critical to international uptake. Patient demand also matters because the company uses direct-to-consumer marketing to drive awareness and prescription requests for a needle-free alternative.
Allergists, pediatricians, and other prescribers who write most epinephrine prescriptions and are targeted because they can drive rapid adoption of neffy.
Wholesale channels that purchase and distribute neffy in the U.S. to pharmacies and healthcare providers.
End users who influence prescribing through preference for a needle-free, easier-to-carry emergency treatment.
Partners such as Alfresa, Pediatrix, Seqirus, and ALK that buy rights, support development, and commercialize in non-U.S. markets.
Clinicians participating in the neffy experience program who use the product firsthand and may convert to prescribing it.
Strategy
ARS’s strategy is to make neffy the standard non-injectable epinephrine option by building physician awareness, patient demand, and payer access around a differentiated delivery method. In the U.S., it is concentrating on a focused sales force aimed at the highest-prescribing allergists and pediatricians, while also using direct-to-consumer marketing to create pull-through demand. Internationally, the company is using licensing and collaboration agreements to extend reach without building a large direct commercial footprint in every market. It is also pursuing pipeline expansion into chronic spontaneous urticaria, which could broaden the platform beyond emergency anaphylaxis treatment if clinical data support it.
The company’s near-term value depends on converting physician awareness into repeat prescribing and pharmacy fulfillment.
Direct consumer demand can support physician adoption and reduce reliance on field sales alone.
Partner-led commercialization can broaden geographic reach while limiting direct operating expense.
A successful second indication could diversify the company beyond anaphylaxis and extend the neffy platform.
Geography
Q1/2026ARS is commercially anchored in the United States, where it launched neffy in September 2024 and generated the majority of revenue from product sales. The company also has approved products or rights in the European Union, the U.K., Japan, Australia, and China, but those markets are largely served through partners rather than a direct local sales force. Its collaboration structure splits territories among Alfresa, Pediatrix, Seqirus, and ALK, which reduces direct operating burden but increases dependence on partner execution. Geography matters because pricing, reimbursement, and regulatory pathways differ materially across the U.S., Europe, and Asia, affecting launch timing and adoption. The company’s manufacturing and supply chain are not fully detailed in the excerpts, but its business model depends on third-party manufacturers, logistics providers, and regulatory approval of raw material sources across markets.
Share of the revenue the company reports by geography.
Risks
ARS is highly dependent on the commercial success of neffy, so slower-than-expected physician adoption, payer resistance, or competitive injectable alternatives could materially limit revenue growth. Because the company relies on third-party manufacturers, logistics providers, CROs, and licensing partners, supply interruptions or partner underperformance could delay sales, require regulatory re-approval of raw materials, or reduce milestone and royalty income. As a commercial-stage biopharma company with a limited product base, it also faces the usual pharmaceutical risks around safety, labeling, reimbursement, and regulatory scrutiny in each market. Cybersecurity and data protection risks are relevant because the company uses cloud systems and third-party service providers to process sensitive clinical, commercial, and operational information. Ongoing losses and dependence on future product uptake mean that execution risk remains high until neffy generates durable, scaled demand.
- Commercial dependence on neffyImpact: CriticalLikelihood: Medium
The company’s business model is concentrated in one approved product, so weak uptake would directly pressure revenue and valuation.
Exposure: U.S. and ex-U.S. epinephrine markets
- Supply chain and third-party manufacturing disruptionImpact: HighLikelihood: Medium
The company relies on external manufacturers and suppliers; interruptions can delay production and require regulatory re-qualification of sources.
Exposure: Global manufacturing and distribution
- Partner underperformanceImpact: HighLikelihood: Medium
International revenue and milestone opportunities depend on collaborators such as ALK, Alfresa, Pediatrix, and Seqirus.
Exposure - Pricing and reimbursement pressureImpact: MediumLikelihood: Medium
Prescription drug pricing can be controlled or negotiated by governments and payers, slowing uptake and reducing realized value.
Exposure - Cybersecurity and data protectionImpact: MediumLikelihood: Medium
The company depends on cloud infrastructure, third-party providers, and remote work, increasing exposure to breaches and operational disruption.
Exposure: Internal systems and outsourced service providers
Accounting
Judgemental itemsRevenue includes product sales plus milestones, royalties, services, and supply arrangements, each with different recognition timing.
Impact: Can shift revenue between quarters and affect gross margin presentation
Net product revenue requires estimates for rebates, chargebacks, returns, and other deductions.
Impact: Can materially change reported net sales as the launch scales
The company noted inventory reserves and the use of zero-cost inventory in early sales periods.
Impact: Can distort gross margin during the launch phase
Equity awards are a meaningful expense for a commercial-stage biopharma company with limited operating history.
Impact: Affects operating loss and comparability across periods
Persistent losses and accumulated deficit require judgment on realizability of tax assets.
Impact: Can affect tax expense and equity presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Nasus Pharma Ltd
NSRX · Pharmaceutical Preparations
Nasus Pharma Ltd is a clinical-stage pharmaceutical company focused on developing innovative intranasal drug products.
Apellis Pharmaceuticals, Inc.
Pharmaceutical Preparations
Apellis Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company built around complement inhibition, with pegcetacoplan as its core molecule.
Arvinas, Inc
ARVN · Pharmaceutical Preparations
Alumis Inc
ALMS · Pharmaceutical Preparations
Can-Fite BioPharma Ltd.
CANF · Pharmaceutical Preparations
Aquestive Therapeutics, Inc.
AQST · Pharmaceutical Preparations
Aquestive Therapeutics is a U.S.-based pharmaceutical company focused on developing and manufacturing medicines that use proprietary delivery technologies to make complex drugs easier to administer.
Last updated: 24/09/2026